GLP-1 Receptor Agonist Market

May 2021| MRS231A| Market Research Studies

Report Highlights

The report focused on the different drugs and brands of glp-1 receptor agonists. The report also focused on the affected age group by meningococcal infection. Furthermore, the scope of the report also covers the impact of COVID-19 and drivers and challenges for GLP-1 Receptor Agonist market. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each drug class, application, route of administration, end-user and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional glp-1 receptor agonist markets; it explains the major market drivers of the global glp-1 receptor agonist industry, current trends within the industry, major applications, and the regional dynamics of the global glp-1 receptor agonist market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the global glp-1 receptor agonist market.

Report Includes

  • 38 tables and 46 figures
  • An up-to-date analysis of the Global GLP-1 Receptor Agonist Market.
  • Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
  • Estimation of market size and revenue forecast for global glp-1 receptor agonist market, and corresponding market share analysis by drug class, application, route of administration, end-user, and region.
  • Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for glp-1 receptor agonist, identification of the companies that are best positioned to meet this demand.
  • In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
  • Identification of promising new drugs, and products still in the development and testing stages, and their probability of successful commercial launch within the next five years
  • Impact of COVID-19 on the GLP-1 Receptor Agonist Market as compared to overall global economy.
  • Insight into the growth development strategies of major GLP-1 Receptor Agonist manufacturers and their key competitive landscape
  • Descriptive company profiles of the leading market participants, including Eli Lilly and Company, Sanofi S.A., Novo Nordisk A/S, AstraZeneca plc, Boehringer Ingelheim GmbH, and others.

Summary

GLP-1 known for glucagon-like peptide is a sort of peptide hormone recognized as incretin hormone which is 30 or 31 long amino acid. GLP-1 receptor agonists are identified in a class named incretin mimetics which aids the pancreas to distribute the optimum amount of insulin.

The role of these drugs is to lower blood glucose levels specifically, hemoglobin A1C. The drug also has several other healthcare benefits including, optimistic effects on cholesterol levels, blood pressure, and beta-cell function. These drugs could be administered by mode of route namely, parenteral, and oral.

In 2020, 9 Meters Biopharma, a GI company, has begun dosing NM-002 (long-acting GLP-1 receptor agonist), which is designed especially for curing gastric motility by decelerating down the digestive transit time.
The GLP-1 receptor agonist has shown significant improvement in reducing the body weight and improving the glycaemic parameters. Some of the GLP-1 receptor agonists which have been approved by the United States Food and Drug Administration for the treatment of type-2 diabetes mellitus includes liraglutide, exenatide, albiglutide, lixisenatide , and dulaglutide.

The Global GLP-1 Receptor Agonist Market was valued at $10.54 billion in 2020 and is expected to witness a steady growth at a CAGR of 7.46% during the forecast period.

  • Table 1 : Global GLP-1 Receptor Agonist Market, Through 2026
  • Table 2 : Global GLP-1 Receptor Agonist Market, by Drug Class, Through 2026
  • Table 3 : Global GLP-1 Receptor Agonist Market, by Application, Through 2026
  • Table 4 : Global GLP-1 Receptor Agonist Market, by Route of Administration, Through 2026
  • Table 5 : Global GLP-1 Receptor Agonist Market, by End-User, Through 2026
  • Table 6 : Global GLP-1 Receptor Agonist Market, by Region, Through 2026
  • Table 7 : North America GLP-1 Receptor Agonist Market, by Drug Class, Through 2026
  • Table 8 : North America GLP-1 Receptor Agonist Market, by Application, Through 2026
  • Table 9 : North America GLP-1 Receptor Agonist Market, by Route of Administration, Through 2026
  • Table 10 : North America GLP-1 Receptor Agonist Market, by End-User, Through 2026
  • Table 11 : North America GLP-1 Receptor Agonist Market, by Country, Through 2026
  • Table 12 : Europe GLP-1 Receptor Agonist Market, by Drug Class, Through 2026
  • Table 13 : Europe GLP-1 Receptor Agonist Market, by Application, Through 2026
  • Table 14 : Europe GLP-1 Receptor Agonist Market, by Route of Administration, Through 2026
  • Table 15 : Europe GLP-1 Receptor Agonist Market, by End-User, Through 2026
  • Table 16 : Europe GLP-1 Receptor Agonist Market, by Country, Through 2026
  • Table 17 : Asia-Pacific GLP-1 Receptor Agonist Market, by Drug Class, Through 2026
  • Table 18 : Asia-Pacific GLP-1 Receptor Agonist Market, by Application, Through 2026
  • Table 19 : Asia-Pacific GLP-1 Receptor Agonist Market, by Route of Administration, Through 2026
  • Table 20 : Asia-Pacific GLP-1 Receptor Agonist Market, by End-User, Through 2026
  • Table 21 : Asia-Pacific GLP-1 Receptor Agonist Market, by Country, Through 2026
  • Table 22 : South America GLP-1 Receptor Agonist Market, by Drug Class, Through 2026
  • Table 23 : South America GLP-1 Receptor Agonist Market, by Application, Through 2026
  • Table 24 : South America GLP-1 Receptor Agonist Market, by Route of Administration, Through 2026
  • Table 25 : South America GLP-1 Receptor Agonist Market, by End-User, Through 2026
  • Table 26 : South America GLP-1 Receptor Agonist Market, by Country, Through 2026
  • Table 27 : Middle East & Africa GLP-1 Receptor Agonist Market, by Drug Class, Through 2026
  • Table 28 : Middle East & Africa GLP-1 Receptor Agonist Market, by Application, Through 2026
  • Table 29 : Middle East & Africa GLP-1 Receptor Agonist Market, by Route of Administration, Through 2026
  • Table 30 : Middle East & Africa GLP-1 Receptor Agonist Market, by End-User, Through 2026
  • Table 31 : Middle East & Africa GLP-1 Receptor Agonist Market, by Country, Through 2026
  • Table 32 : Eli Lilly and Company: Financial Performance, Through 2020
  • Table 33 : Sanofi S.A.: Financial Performance, Through 2020
  • Table 34 : Novo Nordisk A/S: Financial Performance, Through 2020
  • Table 35 : AstraZeneca plc: Financial Performance, Through 2020
  • Table 36 : Boehringer Ingelheim GmbH: Financial Performance, Through 2020
  • Table 37 : Hanmi Pharmaceutical co., ltd.: Financial Performance, Through 2020
  • Table 38 : GlaxoSmithKline plc: Financial Performance, Through 2020
  • Figure 1 : Global GLP-1 Receptor Agonist Market
  • Figure 2 : Global GLP-1 Receptor Agonist Market, by Value, 2019-2026
  • Figure 3 : Global GLP-1 Receptor Agonist Market, by Value, by Drug Class, 2019-2026
  • Figure 4 : Global GLP-1 Receptor Agonist Market, by Value, by Application, 2019-2026
  • Figure 5 : Global GLP-1 Receptor Agonist Market, by Value, by Route of Administration, 2019-2026
  • Figure 6 : Global GLP-1 Receptor Agonist Market, by Value, by End-User, 2019-2026
  • Figure 7 : Global GLP-1 Receptor Agonist Market, by Value, by Region, 2020
  • Figure 8 : Global GLP-1 Receptor Agonist Market, by Value, by Company, 2020
  • Figure 9 : Global GLP-1 Receptor Agonist Market, Product Map, 2020
  • Figure 10 : North America GLP-1 Receptor Agonist Market, by Value, 2019-2026
  • Figure 11 : North America GLP-1 Receptor Agonist Market, by Value, by Drug Class, 2019-2026
  • Figure 12 : North America GLP-1 Receptor Agonist Market, by Value, by Application, 2019-2026
  • Figure 13 : North America GLP-1 Receptor Agonist Market, by Value, by Route of Administration, 2019-2026
  • Figure 14 : North America GLP-1 Receptor Agonist Market, by Value, by End-User, 2019-2026
  • Figure 15 : North America GLP-1 Receptor Agonist Market, by Value, by Country, 2020
  • Figure 16 : Europe GLP-1 Receptor Agonist Market, by Value, 2019-2026
  • Figure 17 : Europe GLP-1 Receptor Agonist Market, by Value, by Drug Class, 2019-2026
  • Figure 18 : Europe GLP-1 Receptor Agonist Market, by Value, by Application, 2019-2026
  • Figure 19 : Europe GLP-1 Receptor Agonist Market, by Value, by Route of Administration, 2019-2026
  • Figure 20 : Europe GLP-1 Receptor Agonist Market, by Value, by End-User, 2019-2026
  • Figure 21 : Europe GLP-1 Receptor Agonist Market, by Value, by Country, 2020
  • Figure 22 : Asia-Pacific GLP-1 Receptor Agonist Market, by Value, 2019-2026
  • Figure 23 : Asia-Pacific GLP-1 Receptor Agonist Market, by Value, by Drug Class, 2019-2026
  • Figure 24 : Asia-Pacific GLP-1 Receptor Agonist Market, by Value, by Application, 2019-2026
  • Figure 25 : Asia-Pacific GLP-1 Receptor Agonist Market, by Value, by Route of Administration, 2019-2026
  • Figure 26 : Asia-Pacific GLP-1 Receptor Agonist Market, by Value, by End-User, 2019-2026
  • Figure 27 : Asia-Pacific GLP-1 Receptor Agonist Market, by Value, by Country, 2020
  • Figure 28 : South America GLP-1 Receptor Agonist Market, by Value, 2019-2026
  • Figure 29 : South America GLP-1 Receptor Agonist Market, by Value, by Drug Class, 2019-2026
  • Figure 30 : South America GLP-1 Receptor Agonist Market, by Value, by Application, 2019-2026
  • Figure 31 : South America GLP-1 Receptor Agonist Market, by Value, by Route of Administration, 2019-2026
  • Figure 32 : South America GLP-1 Receptor Agonist Market, by Value, by End-User, 2019-2026
  • Figure 33 : South America GLP-1 Receptor Agonist Market, by Value, by Country, 2020
  • Figure 34 : Middle East & Africa GLP-1 Receptor Agonist Market, by Value, 2019-2026
  • Figure 35 : Middle East & Africa GLP-1 Receptor Agonist Market, by Value, by Drug Class, 2019-2026
  • Figure 36 : Middle East & Africa GLP-1 Receptor Agonist Market, by Value, by Application, 2019-2026
  • Figure 37 : Middle East & Africa GLP-1 Receptor Agonist Market, by Value, by Route of Administration, 2019-2026
  • Figure 38 : Middle East & Africa GLP-1 Receptor Agonist Market, by Value, by End-User, 2019-2026
  • Figure 39 : Middle East & Africa GLP-1 Receptor Agonist Market, by Value, by Country, 2020
  • Figure 40 : Eli Lilly and Company: Revenue Share, 2020
  • Figure 41 : Sanofi S.A.: Revenue Share, 2020
  • Figure 42 : Novo Nordisk A/S: Revenue Share, 2020
  • Figure 43 : AstraZeneca plc: Revenue Share, 2020
  • Figure 44 : Boehringer Ingelheim GmbH: Revenue Share, 2020
  • Figure 45 : Hanmi Pharmaceutical co., ltd.: Revenue Share, 2020
  • Figure 46 : GlaxoSmithKline plc: Revenue Share, 2020

Market Research Studies is a North Carolina based, premier market research company. MRS brings over 50 years of market research publishing experience. Our reports cover a variety of industries such as Healthcare, Chemicals, Materials & Manufacturing, Research & Diagnostics, Environment & Sustainability, among others. Each year MRS releases hundreds of reports covering various topics. These reports are prepared by our in-house of team of Industry expert analysts. We strive to provide in-depth market analysis with accurate data to help our customers make informed decisions.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report